The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors.
Shannon Neville Westin
No relevant relationships to disclose
Melody L. Smart
No relevant relationships to disclose
Navdeep Pal
No relevant relationships to disclose
Diana L Urbauer
No relevant relationships to disclose
Filip Janku
Research Funding - Biocartis; Novartis; Roche; Transgenomic; Trovagene
Jennifer J. Wheler
No relevant relationships to disclose
Sarina Anne Piha-Paul
No relevant relationships to disclose
Aung Naing
No relevant relationships to disclose
Apostolia Maria Tsimberidou
No relevant relationships to disclose
Siqing Fu
No relevant relationships to disclose
Gerald Steven Falchook
No relevant relationships to disclose
David S. Hong
No relevant relationships to disclose
Ralph Zinner
No relevant relationships to disclose
Vivek Subbiah
No relevant relationships to disclose
Kirk Salvatore Culotta
No relevant relationships to disclose
Karen H. Lu
No relevant relationships to disclose
Robert L. Coleman
Honoraria - Genentech
Research Funding - Genentech
Razelle Kurzrock
Research Funding - Genentech; Roche